OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 
ASCO Annual Meeting 
Expanding OGX-427 Clinical Development Program Demonstrates the Company's 
Commitment to Addressing the Challenge of Cancer Treatment Resistance 
"Trials in Progress" Posters will be Presented for Investigational Compounds 
Custirsen and OGX-427 across Multiple Tumor Types 
BOTHELL, Wash. and VANCOUVER, British Columbia, May 22, 2013 /CNW/ - OncoGenex 
Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel 
therapeutics to target mechanisms of treatment resistance in cancer, today 
announced that four trials of its investigational compounds, custirsen and 
OGX-427, will be presented as "Trials in Progress" posters at the 49(th) 
Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, 
IL from May 31 – June 4. 
Despite the availability of drugs that improve survival in patients with 
cancer, treatment failure attributed to resistance continues to be a major 
problem in medical oncology.(1,2,3,4)  Across multiple tumor types, the 
majority of patients with cancer are likely to face treatment resistance at 
some point.(4,5,6) 
"At this year's ASCO we're highlighting the breadth and depth of our clinical 
development programs, which evaluate innovative therapies that target 
important mechanisms of cancer treatment resistance in a variety of cancers," 
said Scott Cormack, President and Chief Executive Officer, OncoGenex 
Pharmaceuticals, Inc. "With three Phase 3 trials for custirsen ongoing and 
multiple Phase 2 trials for OGX-427 underway, our development programs have 
never been stronger." 
At ASCO, details will be presented on trial design and rationale for the Phase 
3 AFFINITY trial. Additionally, three of five Phase 2 trials from the OGX-427 
ORCA™ (Ongoing Studies Evaluating Treatment Resistance in CAncer) clinical 
trial program will be highlighted. 


    --  Abstract #TPS5103: Design of the AFFINITY study: A randomized
        phase III study of a novel clusterin inhibitor, custirsen, plus
        cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line
        chemotherapy in metastatic castration-resistant prostate cancer
        (mCRPC) (June 3, 2013)
    --  Abstract #TPS4588^: The Borealis-2 clinical trial: A randomized
        phase II study of OGX-427 plus docetaxel versus docetaxel alone
        in relapsed/refractory metastatic urothelial cancer (June 3,
        2013)
    --  Abstract #TPS8120: Double-blind randomized phase II trial of
        carboplatin and pemetrexed with or without OGX-427 in patients
        with previously untreated stage IV non-squamous non-small-cell
        lung cancer (NSCLC): The Spruce Clinical Trial (June 1, 2013)
    --  Abstract #TPS5101: The Pacific trial: A randomized phase II
        study of OGX-427 in men with metastatic castration-resistant
        prostate cancer (mCRPC) and PSA progression while receiving
        abiraterone acetate (AA) (June 3, 2013)

Visit the OncoGenex booth, #22030, at ASCO to find out more about the ORCA and 
custirsen clinical trial programs.

ABOUT CUSTIRSEN  Custirsen is an experimental drug that is designed to block 
the production of the protein clusterin, which may play a fundamental role in 
cancer cell survival and treatment resistance. Clusterin is upregulated in 
tumor cells in response to treatment interventions such as chemotherapy, 
hormone ablation and radiation therapy and has been found to be overexpressed 
in a number of cancers, including prostate, lung, breast and bladder.

The primary registration Phase 3 SYNERGY trial, designed to evaluate a 
survival benefit for custirsen in combination with first-line docetaxel 
chemotherapy in men with metastatic CRPC, completed enrollment in 2012. 
OncoGenex recently announced the SYNERGY trial is continuing as planned per 
the recommendation of an independent Data Monitoring Committee after 
completion of the last planned futility analyses.

ABOUT OGX-427 and ORCA™  OGX-427 is a once-weekly intravenous (IV) drug that 
is designed to inhibit production of heat shock protein (Hsp27) to disable 
cancer cells' defenses and overcome treatment resistance. Hsp27 is an 
intracellular protein that protects cancer cells by helping them survive, 
leading to resistance and more aggressive cancer phenotypes.

The ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program 
encompasses clinical trials of OGX-427 aiming to demonstrate whether 
inhibition of heat shock protein 27 (Hsp27) can lead to improved prognosis and 
treatment outcomes for patients with specific types of cancer. Phase 2 
clinical trials are underway in bladder, lung, pancreatic and prostate 
cancers, with additional updates to the ORCA program expected to be provided 
later this year. For more information on OGX-427 and ORCA, please visit 
www.OncoGenex.com.

ABOUT ONCOGENEX OncoGenex is a biopharmaceutical company committed to the 
development and commercialization of new therapies that address treatment 
resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with 
each product candidate having a distinct mechanism of action and representing 
a unique opportunity for cancer drug development. OncoGenex and Teva 
Pharmaceutical Industries Ltd. have entered a global collaboration and license 
agreement to develop and commercialize OncoGenex' lead drug candidate, 
custirsen. Custirsen is currently in Phase 3 clinical development as a 
treatment in men with metastatic castrate-resistant prostate cancer and in 
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in 
Phase 2 clinical development and OGX-225 is currently in pre-clinical 
development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements  This press release contains 
forward-looking statements within the meaning of the "safe harbor" provisions 
of the Private Securities Litigation Reform Act of 1995, including, but not 
limited to, statements concerning our anticipated product development 
activities, such as expected clinical trial completion and design and 
statements regarding the potential benefits and potential development of our 
product candidates. All statements other than statements of historical fact 
are statements that could be deemed forward-looking statements. These 
statements are based on management's current expectations and beliefs and are 
subject to a number of risks, uncertainties and assumptions that could cause 
actual results to differ materially from those described in the 
forward-looking statements, including, among others, the risk that our product 
candidates will not demonstrate the hypothesized or expected benefits, the 
risk of delays in our expected clinical trials, the risk that new developments 
in the rapidly evolving cancer therapy landscape require changes in our 
clinical trial plans or limit the potential benefits of our product candidates 
and the other factors described in our risk factors set forth in our filings 
with the Securities and Exchange Commission from time to time, including the 
Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The 
Company undertakes no obligation to update the forward-looking statements 
contained herein or to reflect events or circumstances occurring after the 
date hereof, other than as may be required by applicable law.

ORCA™, Pacific™, Borealis-2™ and Spruce™ are registered trademarks of 
OncoGenex Pharmaceuticals, Inc.

(1) Brunton LB, Chabner BA, Knollman B. General principles of cancer 
chemotherapy: introduction. In: Goodman & Gilman's The Pharmacological. 12th 
ed. New York, NY: The McGraw-Hill Companies; 2010:x-x.

(2) Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex 
and integrated cellular response. Pharmacology. 2008;81(4):275-292.

(3) Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J 
Pathol. 2005;205(2):275-292.

(4) Lippert TH, Ruoff H-J, Volm M. Current status of methods to assess cancer 
drug resistance. Int J Med Sci. 2011;8(3):245-253.

(5) Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, 
clusterin, for treatment of advanced cancer. Clin Cancer Res. 
2010;16(4):1088-1093.

(6) Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann 
Oncol. 2006;17(suppl 10):x315-x324.

Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403; Investor 
Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535

http://www.OncoGenex.com

SOURCE: OncoGenex Pharmaceuticals, Inc.

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/May2013/22/c8945.html

CO: OncoGenex Pharmaceuticals, Inc.
ST: British Columbia
NI: HEA MTC BTC SHOW 

-0- May/22/2013 10:30 GMT